Search for: [Abstract = "ith mantle cell lymphoma was given every 21 days 3 to 6 cycles of FCM\+\/\-Rituximab chemotherapy. After first 3 cycles of the therapy the patient was qualified for radioimmunotherapy \(RIT\). If the patient did not fulfill the criteria for RIT, next 3 cycles of the therapy were given. Additional bridging dose of Rituximab was administered if the rise of neutrophil count or PLT count was not observed. The 90Y\-Ibritumomab tiuxetan was not implemented in patients not meeting the criteria of the qualification. Statistical analysis was performed using STATISTICA PL \(version 6.0\) package. After the treatment in subgroup of NET patients no statistically important changes in creatinine level and GFR were observed. After 5 months an increase in creatinine level was noticed \(from 73,37 µmol\/l to 86,63 µmol\/l\). A slightly higher rise in creatinine levels was observed in a small subset of patients with longer, 24\-month follow\-up period. Mean creatinine level was 101,66 µmol\/l. None of the patient showed the signs and symptoms related to the deterioration of the kidney function. However, literature data on the delayed nephrotoxicity suggest that the prolonged observation after the treatment with labelled somatostatin analogues is needed. Only minor changes in complete blood count \(CBC\) were seen after completion of the therapy. Mean haemoglobin level decreased after subsequent therapy cycles."]

Number of results: 1